Stomach Cancer Diagnosis
Stomach Cancer Diagnosis
The diagnosis is made by endoscopy and biopsy; everything after that is staging. Each test answers one specific question, and a plan needs all of them before surgery is discussed.
Endoscopy: where the diagnosis is made
Upper gastrointestinal endoscopy — gastroscopy — is the test on which everything else depends. A flexible scope is passed through the mouth into the oesophagus, stomach and first part of the small bowel, the mucosa is inspected systematically, and any suspicious area is photographed and biopsied. It is the standard against which other tests are judged because it does two things at once: it shows the lesion, and it takes the tissue that names it.
Two technical points matter to the quality of the examination. First, the number and placement of biopsies: a visible lesion should be sampled adequately, because a single small biopsy can miss a tumour that is present. Second, systematic inspection — a careful examination documents where the tumour starts and ends and looks at the rest of the stomach, since about a small minority of patients have a second, separate lesion. If your endoscopy report has photographs and a diagram, it is worth more than one that does not.
Endoscopic ultrasound is a separate procedure using an ultrasound probe at the tip of the scope. It shows the five layers of the stomach wall, and therefore answers the question that decides between endoscopic resection and surgery: how deep has the tumour grown, and are the lymph nodes immediately around the stomach abnormal.
Imaging: what each scan is for
Contrast-enhanced CT of the chest, abdomen and pelvis is the primary staging test. It assesses the thickness of the stomach wall, the lymph-node stations that a resection would remove, the liver, and the lungs. It answers the question that decides whether a patient is a surgical candidate at all.
CT or barium studies of the stomach can outline the tumour's extent along the organ, which helps the surgeon plan how much stomach to remove and what reconstruction to use. PET-CT is used selectively — it adds information where CT findings are equivocal, and some gastric cancers take up glucose poorly, which limits what it can exclude. MRI has a place in characterising liver lesions rather than in primary gastric staging.
The honest limitation of all of it: peritoneal spread, the pattern of dissemination that gastric cancer favours, is the thing imaging sees least well. Small deposits on the peritoneal surface are below the resolution of CT. This is the gap that diagnostic laparoscopy exists to close.
Pathology: what the biopsy report should contain
The biopsy report does more than say "cancer". It should state:
- Tumour type — adenocarcinoma, and whether it is intestinal or diffuse type in the Lauren classification, or another subtype such as signet ring cell or hepatoid adenocarcinoma.
- Grade — how differentiated the gland formation is.
- Lymphovascular invasion — whether tumour cells have entered vessels, which raises the risk of spread.
- Presence of H. pylori on the specimen, which has consequences for the stomach as an organ, not just for this tumour.
Pathology is also the link between a diagnosis made years ago and a treatment decision made now: the original slides can be reviewed, and the tissue block can be used for molecular testing without another procedure.
Molecular testing: the report that decides drug therapy
Every gastric adenocarcinoma should be tested for HER2 and MMR/MSI status, and PD-L1 should be reported. These are decided on the biopsy specimen, and they are the reason two patients at the same stage receive different first-line treatment.
- HER2 — positive in a subset of gastric cancers; trastuzumab is added to first-line chemotherapy when it is positive.
- PD-L1 Combined Positive Score — reported on the tumour and immune cells; the score guides whether an anti-PD-1 antibody is added.
- MSI-H or dMMR — predicts benefit from immunotherapy, and can be decisive in later lines when chemotherapy options are limited.
If your biopsy was taken elsewhere and these tests were not done, ask for the block to be sent — testing stored tissue is routine, and repeating an endoscopy only to obtain a sample is almost always avoidable.
Staging, and why laparoscopy is part of it
Gastric cancer is staged by the TNM system: T for depth of wall invasion, N for lymph nodes, M for distant spread. The clinical stage — the one assigned from endoscopy, endoscopic ultrasound, CT and laparoscopy — is what the first treatment decision is based on, because the pathological stage only exists after an operation.
Diagnostic laparoscopy deserves its own explanation, because it is the step most often skipped elsewhere. It is a short procedure under general anaesthesia in which a camera is placed into the abdomen, the peritoneal surface and liver are inspected directly, and samples are taken. It finds the small peritoneal deposits that CT cannot see — the findings that would change a planned gastrectomy into systemic therapy. In locally advanced disease, having this information before surgery is the difference between a well-planned operation and an unplanned one.
Getting a diagnosis reviewed from abroad
Most of the work-up can be reviewed without repeating it. What our team needs is the endoscopy report with photographs, the pathology report, the CT images on a disc or uploaded, and the molecular results if they exist. From that file, a written assessment usually answers the questions the patient is actually carrying: is the stage right, is the endoscopic-resection-versus-surgery question settled, and which drugs does the molecular profile support.
What cannot be assessed remotely is decided here: endoscopic ultrasound and diagnostic laparoscopy are procedures, and they are arranged as part of a single visit rather than as separate trips. Send the records first and the plan tells you which of them you actually need.